Every 8-K that TransMedics Group, Inc. (TMDX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TMDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TMDX filings page.
TransMedics Group, Inc. (TMDX) announced a leadership transition in its finance organization and reiterated its financial outlook. The Board appointed Fernando Araujo as Chief Financial Officer and Treasurer effective September 21, 2026, succeeding Gerardo Hernandez, who will move into advisory and commercial roles through April 2027.
The company reaffirmed its full-year 2026 revenue guidance of $737 million to $757 million, representing approximately 22% to 25% year-over-year growth, excluding any revenue from its investment in PAD Aviation Service GmbH. Araujo’s compensation includes a $590,000 base salary, performance-based bonus eligibility, a $200,000 sign-on bonus, and equity awards, with defined severance and change-in-control protections.
TransMedics Group reported financial results for the quarter ended June 30, 2026. Total revenue was $189.9 million, a 21% increase from $157.4 million in the prior-year quarter, driven by higher utilization of the Organ Care System in liver and heart through the National OCS Program and growth in logistics services. Product revenue was $111.2 million and service revenue was $78.8 million. Net income was $14.7 million, or $0.41 per diluted share, compared with $34.9 million, or $0.92 per diluted share, a year earlier. Adjusted net income was $16.2 million, or $0.44 per diluted share.
Gross margin was 60% versus 61% a year ago. Operating expenses rose to $89.5 million from $60.0 million, reflecting investment in OCS Kidney, next-generation OCS 3.0, clinical programs and infrastructure. Income from operations declined to $23.7 million, for a 12.5% operating margin, compared with $36.6 million and a 23.2% margin in the prior-year quarter. Cash totaled $472.7 million as of June 30, 2026. Management raised the low end of full-year 2026 revenue guidance to a range of $737 million to $757 million, representing approximately 22% to 25% growth versus the prior year and excluding revenue from the strategic investment in PAD Aviation completed on July 1, 2026.
TransMedics Group, Inc. reported the results of its 2026 Annual Meeting of Shareholders. Shareholders elected eight directors, including Waleed Hassanein, M.D. and James R. Tobin, to serve until the 2027 annual meeting or until successors are elected.
They approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 22,871,647 votes in favor, 1,161,181 against and 30,895 abstentions. Shareholders also approved an amendment to the Amended and Restated TransMedics Group, Inc. 2019 Stock Incentive Plan, with 17,265,369 votes for and 6,758,882 against.
In addition, shareholders ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 28,030,696 votes for, 648,359 against and 17,653 abstentions.
TransMedics Group, Inc. reported first quarter 2026 revenue of $173.9 million, up 21% from the prior year, driven mainly by greater use of its Organ Care System for liver and heart in the National OCS Program and growth in logistics services.
Profitability declined as gross margin slipped to 58% from 61% and operating expenses rose to $87.9 million from $60.8 million, reflecting higher research and development and broader investment to support growth. Income from operations fell to $13.3 million from $27.4 million, and net income dropped to $7.3 million with diluted earnings per share of $0.20, compared with $0.70 a year earlier.
On a non-GAAP basis, adjusted income from operations was $18.1 million and adjusted diluted EPS was $0.30, both down from last year. The company reiterated its full-year 2026 revenue outlook of $727–$757 million, implying 20–25% growth, and reported cash of $461.7 million. Management highlighted expansion of its aviation fleet to 22 owned aircraft, a planned investment in Germany-based PAD Aviation to build a European transplant logistics network, and progress on programs such as ENHANCE Heart, DENOVO Lung, the NOP model in Europe, OCS Kidney, and the new CHOPS preservation system.
TransMedics Group, Inc. explains how releasing a U.S. tax valuation allowance changed its previously reported fourth-quarter 2025 results. In Q4 2025 the company released a $103.3 million valuation allowance on deferred tax assets, creating a net income tax benefit of $83.8 million and driving a reported annual effective tax rate of (77.0)%.
For Q4 2025, income before income taxes was $21.6 million. Reported net income was $105.4 million, or $2.62 per diluted share. Using a 19.1% annual effective tax rate excluding the allowance release, adjusted Q4 net income is $17.5 million, or $0.47 per diluted share. The company expects future quarterly tax provisions to align more closely with typical U.S. corporate tax rates.
TransMedics Group, Inc. reported strong growth for the fourth quarter and full year 2025, driven by broader use of its Organ Care System and related services. Fourth quarter revenue reached $160.8 million, up 32% year over year, while full year 2025 revenue rose to $605.5 million, a 37% increase.
Net income jumped to $105.4 million in the fourth quarter and $190.3 million for the full year, helped by a one-time tax benefit from releasing a valuation allowance on deferred tax assets. The company maintained gross margins around 58–60% and increased investment in research, clinical programs, and commercial infrastructure.
TransMedics completed 5,139 U.S. NOP cases in 2025, expanded its owned aviation fleet to 22 aircraft, and received FDA approval for key heart and lung trials. For 2026, it projects revenue between $727 million and $757 million, implying 20% to 25% growth over 2025.
TransMedics Group, Inc. announced leadership transitions in its commercial and legal functions. The Board appointed Giovanni Cecere as Chief Commercial Officer effective February 2, 2026, succeeding Tamer Khayal, M.D., who will become Senior Vice President of International on the same date.
The Board also appointed Matthew Forsyth as Senior Vice President, General Counsel & Corporate Secretary effective March 9, 2026 or his actual start date. Current General Counsel Anil Ranganath will move to a non-executive employee role until June 7, 2026 and then serve as a non-employee consultant until September 7, 2026. His equity awards will continue to vest during his service, and he will receive an annualized consultant fee of $10,000, plus cash severance equal to 0.75 times his highest recent base salary and bonus, COBRA premiums for up to nine months, and a pro-rated 2026 bonus, subject to a release of claims and ongoing covenants.
TransMedics Group, Inc. has signed a long-term lease with BioMed Realty for approximately 498,286 square feet at 188 Assembly Park Drive in Somerville, Massachusetts, which will become its new headquarters and house research, development, lab, manufacturing, assembly, vivarium, office and related functions. The lease term begins on January 8, 2026, with base rent starting on the later of January 1, 2028 or 24 months after term commencement, and running for 192 months from that rent start date.
Initial annual base rent is approximately $23.9 million, increasing 2% each year over the initial term, and the company is expected to bear about 100% of operating and tax expenses for the premises. TransMedics has provided an approximately $18 million letter of credit as a security deposit and holds two 10-year extension options plus a six-month extension option, all subject to customary conditions. Separately, on January 8, 2026, the company acquired two parcels adjacent to the new site in Somerville for $15.0 million each, plus related costs.
TransMedics Group, Inc. (TMDX) furnished an 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.
The company specifies the information is being furnished, not filed, meaning it is not subject to Section 18 liability and will only be incorporated into other filings if expressly referenced. The common stock trades on the Nasdaq Global Market under the symbol TMDX.
TransMedics Group, Inc. filed a Form 8-K disclosing a material event: the company considers certain Acquisitions to be a series of related transactions to acquire a fleet of aircraft for use in its National OCS Program. The filing identifies this as a material event and is signed by Gerardo Hernandez, Chief Financial Officer and Treasurer on October 6, 2025. The notice states the purpose of the aircraft is to support the company’s National OCS Program but provides no financial terms, sources of financing, timelines, or specific aircraft counts in the disclosed text.